Ruthanne Williams Roussel: Data on AMLN Phase II study is at their website and my blog, but short version is: comparable to most Phase II obesity studies
Mon, Nov 02, 2009
Ruthanne Williams Roussel: Outtake from article: AMLN says no big deal that their drug is injectable because many diabetics already inject anyway. I don't agree...
Mon, Nov 02, 2009
Ruthanne Williams Roussel: AMLN news good for all the obesity stocks. It shows there is serious interest among major drug companies in marketing obesity drugs.